Edition:
United Kingdom

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

3.62USD
8:59pm GMT
Change (% chg)

$-0.02 (-0.55%)
Prev Close
$3.64
Open
$3.64
Day's High
$3.76
Day's Low
$3.59
Volume
101,988
Avg. Vol
171,601
52-wk High
$5.25
52-wk Low
$1.93

Chart for

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $329.60
Shares Outstanding(Mil.): 109.14
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Cerus Corp reports Q3 loss per share $0.12

* Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio

* Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy

31 Oct 2017

BRIEF-Cerus announces agreement with transfusion Center of the Community of Madrid

* Cerus announces agreement with transfusion Center of the Community of Madrid

30 Oct 2017

BRIEF-CERUS ANNOUNCES NATIONAL GERMAN REIMBURSEMENT FOR PATHOGEN INACTIVATED PLATELETS

* CERUS SAYS ‍INSTITUTE FOR HOSPITAL REMUNERATION SYSTEM IN GERMANY WILL INCLUDE PATHOGEN-INACTIVATED PLATELETS FOR NATIONAL REIMBURSEMENT STARTING JAN 1, 2018​ Source text for Eikon: Further company coverage:

23 Oct 2017

BRIEF-Cerus Corp files for mixed shelf of up to $250 mln - SEC filing‍​

* Cerus Corp files for mixed shelf of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2wfbOni) Further company coverage:

04 Aug 2017

BRIEF-Cerus Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

03 Aug 2017

BRIEF-Cerus enters into $40 mln amended growth capital agreement

* Cerus enters into $40 million amended growth capital agreement

02 Aug 2017

BRIEF-Cerus expands agreement with French National Blood Service

* Cerus announces expanded supply agreement with french national blood service

01 Aug 2017

Competitors

  Price Chg
Terumo Corp (4543.T) ¥5,240 --
Grifols SA (GRLS.MC) €24.43 +0.35
Grifols SA (GRLSbn.MC) €18.39 -0.16

Earnings vs. Estimates